Oncology Pre-Clinical & Clinical Assets

The success rate for reaching a molecule from the R&D stage to the Phase I clinical stage is below 10% and the average time for a drug/biologics development to get NDA/BLA status is 8.3 years.

The client approached us to identify the preclinical/early clinical trial candidates that have shown potential activity in pre-clinical/early clinical studies so that the client can collaborate with the original innovator and evaluate them in further clinical studies. We have conducted an exploratory study by analyzing literature & early clinical trials data to identify the target assets which address the unmet needs of the therapeutic domain and have the high potential to complete advanced clinical trials to become a successful drug.